Compare Incyte Corporation (INCY) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tripadvisor Inc Common Stock — how do they compare? Incyte Corporation trades at $117.98 (market cap $23.11B), while Tripadvisor Inc Common Stock trades at $13.86 (market cap $1.68B). The key difference: Incyte Corporation is far larger — about 13.8× Tripadvisor Inc Common Stock's market cap, and Incyte Corporation is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| INCY | TRIP | |
|---|---|---|
Market Cap | $23.11B | $1.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $19.14 |
52-Week Low | $67.38 | $9.24 |
Enterprise Value | $19.13B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Tripadvisor (TRIP) trades at $14.38, down 1.37% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported Q1 2026 earnings miss but maintains strong gross margins of 91.95%. Recent $700 million sale of TheFork to American Express provides capital flexibility while focusing on core travel experiences business. Revenue growth remains modest at $1.89B in 2025 with net margin improving to 2.11%.
Outlook remains cautious with analyst consensus at Hold (60.72%) and $13.87 price target below current levels. The stock faces headwinds from competitive pressures and macroeconomic uncertainty, though the strategic divestiture and travel recovery trends offer potential upside. Key risks include execution challenges and market volatility amid mixed earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
